EA202090449A1 - BINDING AGENTS, BINDING PD-L1 AND CD137 AND THEIR APPLICATION - Google Patents

BINDING AGENTS, BINDING PD-L1 AND CD137 AND THEIR APPLICATION

Info

Publication number
EA202090449A1
EA202090449A1 EA202090449A EA202090449A EA202090449A1 EA 202090449 A1 EA202090449 A1 EA 202090449A1 EA 202090449 A EA202090449 A EA 202090449A EA 202090449 A EA202090449 A EA 202090449A EA 202090449 A1 EA202090449 A1 EA 202090449A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding
application
binding agents
antibodies
agents
Prior art date
Application number
EA202090449A
Other languages
Russian (ru)
Inventor
Изил Алтинтас
Давид Сатейн
Рик Радемакер
Паул Паррен
Угур САХИН
Фридерике ГИСЕКЕ
Александер Муйк
Кристиан Грунвиц
Original Assignee
Генмаб А/С
Бионтех Се
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Генмаб А/С, Бионтех Се filed Critical Генмаб А/С
Priority claimed from PCT/EP2018/071002 external-priority patent/WO2019025545A1/en
Publication of EA202090449A1 publication Critical patent/EA202090449A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к новым связывающим агентам и их применению в медицине. В особенности, изобретение относится к связывающим агентам, таким как биспецифические антитела, связывающие человеческий PD-L1 и связывающие человеческий CD137. Изобретение, кроме того, относится к применению антител изобретения и к способам, конструкциям нуклеиновых кислот и клеткам-хозяевам для продуцирования антител изобретения.The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies that bind human PD-L1 and bind human CD137. The invention further relates to the use of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing the antibodies of the invention.

EA202090449A 2018-02-06 2018-08-02 BINDING AGENTS, BINDING PD-L1 AND CD137 AND THEIR APPLICATION EA202090449A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018052946 2018-02-06
PCT/EP2018/071002 WO2019025545A1 (en) 2017-08-04 2018-08-02 Binding agents binding to pd-l1 and cd137 and use thereof

Publications (1)

Publication Number Publication Date
EA202090449A1 true EA202090449A1 (en) 2020-07-01

Family

ID=71833504

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090449A EA202090449A1 (en) 2018-02-06 2018-08-02 BINDING AGENTS, BINDING PD-L1 AND CD137 AND THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA202090449A1 (en)

Similar Documents

Publication Publication Date Title
SA520411173B1 (en) Binding Agents Binding to PD-L1 and CD137 and Use Thereof
ZA201905822B (en) Antibodies against pd-l1
EA201791961A1 (en) ANTIBODIES SPECIFIC TO CD47 AND PD-L1
EA202091710A1 (en) ANTIBODIES AGAINST CD73 AND METHODS OF THEIR USE
JOP20200313A1 (en) Dll3-cd3 bispecific antibodies
EA201991383A1 (en) ANTIBODIES AGAINST CTLA-4 AND WAYS OF THEIR APPLICATION
MX2021011696A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123.
MX2022009306A (en) Cd28 single domain antibodies and multivalent and multispecific constructs thereof.
EA201892616A1 (en) ANTIBODIES TO PD1 AND LAG3 FOR THE TREATMENT OF MALIGNANT NUMER FORMATION
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
EA201890630A1 (en) ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
EA202092735A1 (en) ANTAGONIZING CD73 ANTIBODY
EA201792573A1 (en) TRISPECIFIC RELATED PROTEINS AND METHODS OF THEIR APPLICATION
EA201890443A1 (en) BISPECIFIC MONOVALENT DIATELS, ABLE TO CONNECT B7-H3 AND CD3 AND THEIR APPLICATION
PH12019500571A1 (en) Anti-pd-1 antibodies
BR112017010110A2 (en) antibodies to cd73 and uses thereof
EA201990321A1 (en) BISPECIFIC ANTI-CURRENT BINDING PROTEINS THAT SPECIFICALLY BIND TO CD3 AND CD123
EA201590138A1 (en) OPTIMIZATION OF ANTIBODIES THAT BIND THE ACTIVATION GENE OF LYMPHOCYTES 3 (LAG-3) AND THEIR USE
EA201290570A1 (en) CONSTRUCTIONS CONNECTING WITH RON AND METHODS OF THEIR USE
MX2017001403A (en) Bispecific single chain antibody construct with enhanced tissue distribution.
MX2015008446A (en) Multivalent binding protein compositions.
EA201992206A1 (en) MONOCLONAL ANTIBODY TO PD-L1
EA201101516A1 (en) ANTIBODIES SPECIFIC FOR KADGERINA-17
EA201892774A1 (en) ANTIBODIES
EA201890941A1 (en) PROGRAMMABLE UNIVERSAL CELL RECEPTORS AND METHODS OF THEIR APPLICATION